Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017, Article ID 7905148, 8 pages
https://doi.org/10.1155/2017/7905148
Research Article

Oxidative Modification of Blood Serum Proteins in Multiple Sclerosis after Interferon Beta and Melatonin Treatment

1Department of Neurology in Zabrze, Medical University of Silesia, 3-go Maja St. 13-15, 41-800 Zabrze, Poland
2Department of Histology and Embryology, Chair of the Morphological Sciences, University of Rzeszów, Leszka Czarnego 4, 35-615 Rzeszów, Poland
3Department of Analytical Biochemistry, Faculty of Biology and Agriculture, University of Rzeszów, ul. Zelwerowicza 4, 35-601 Rzeszów, Poland
4Department of Laryngology in Zabrze, Medical University of Silesia, ul. Curie-Skłodowskiej 10, 41-800 Zabrze, Poland
5Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Łódź, Pomorska 141/143, 90-236 Łódź, Poland

Correspondence should be addressed to Izabela Sadowska-Bartosz; mf.atzcop@akswodasi

Received 22 May 2017; Accepted 24 September 2017; Published 18 October 2017

Academic Editor: Valentina Pallottini

Copyright © 2017 Monika Adamczyk-Sowa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Dhib-Jalbut, “Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis,” Neurology, vol. 58, Supplement 4, no. 8, pp. S3–S9, 2002. View at Publisher · View at Google Scholar
  2. S. Dhib-Jalbut and S. Marks, “Interferon-β mechanisms of action in multiple sclerosis,” Neurology, vol. 74, Supplement 1, pp. S17–S24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Haider, M. T. Fischer, J. M. Frischer et al., “Oxidative damage in multiple sclerosis lesions,” Brain, vol. 134, no. 7, pp. 1914–1924, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Wang, K. Xie, C. Wang, and J. Bi, “Oxidative stress induced by lipid peroxidation is related with inflammation of demyelination and neurodegeneration in multiple sclerosis,” European Neurology, vol. 72, no. 3-4, pp. 249–254, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Mir, D. Lee, H. Ray, and S. A. Sadiq, “CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis,” Neurology-Neuroimmunology Neuroinflammation, vol. 1, no. 2, article e21, 2014. View at Publisher · View at Google Scholar
  6. S. R. Oliveira, A. P. Kallaur, A. N. Simão et al., “Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale,” Journal of the Neurological Sciences, vol. 321, no. 1-2, pp. 49–53, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Fiorini, T. Koudriavtseva, E. Bucaj et al., “Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis,” PLoS One, vol. 8, no. 6, article 65184, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Mehrzadi, M. Safa, S. K. Kamrava, R. Darabi, P. Hayat, and M. Motevalian, “Protective mechanisms of melatonin against hydrogen-peroxide-induced toxicity in human bone-marrow-derived mesenchymal stem cells,” Canadian Journal of Physiology and Pharmacology, vol. 95, no. 7, pp. 773–786, 2016. View at Publisher · View at Google Scholar
  9. S. R. Pandi-Perumal, A. S. BaHammam, G. M. Brown et al., “Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes,” Neurotoxicity Research, vol. 23, no. 3, pp. 267–300, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. U. Rimmele, M. Spillmann, C. Bärtschi et al., “Melatonin improves memory acquisition under stress independent of stress hormone release,” Psychopharmacology, vol. 202, no. 4, pp. 663–672, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Baydas, M. Özera, A. Yasara, M. Tuzcu, and S. T. Koz, “Melatonin improves learning and memory performances impaired by hyperhomocysteinemia in rats,” Brain Research, vol. 1046, no. 1-2, pp. 187–194, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Sharif, M. Aghsami, M. Gharghabi et al., “Melatonin reverses H-89 induced spatial memory deficit: involvement of oxidative stress and mitochondrial function,” Behavioural Brain Research, vol. 316, pp. 115–124, 2017. View at Publisher · View at Google Scholar
  13. J. Wen, P. S. Ariyannur, R. Ribeiro et al., “Efficacy of N-acetylserotonin and melatonin in the EAE model of multiple sclerosis,” Journal of Neuroimmune Pharmacology, vol. 11, no. 4, pp. 763–773, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Sadowska-Bartosz, M. Adamczyk-Sowa, S. Galiniak, S. Mucha, K. Pierzchala, and G. Bartosz, “Oxidative modification of serum proteins in multiple sclerosis,” Neurochemistry International, vol. 63, no. 4, pp. 507–516, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Sadowska-Bartosz, M. Adamczyk-Sowa, A. Gajewska, and G. Bartosz, “Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment,” Journal of Neuroimmunology, vol. 266, no. 1-2, pp. 67–74, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983. View at Publisher · View at Google Scholar
  17. P. Schwenkenbecher, A. Sarikidi, U. Wurster et al., “McDonald criteria 2010 and 2005 compared: persistence of high oligoclonal band prevalence despite almost doubled diagnostic sensitivity,” International Journal of Molecular Sciences, vol. 17, no. 9, article 1592, 2016. View at Google Scholar
  18. G. L. Ellman, “Tissue sulfhydryl groups,” Archives of Biochemistry and Biophysics, vol. 82, no. 1, pp. 70–77, 1959. View at Publisher · View at Google Scholar
  19. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951. View at Google Scholar
  20. V. Witko-Sarsat, M. Friedlander, C. Capeillère-Blandin et al., “Advanced oxidation protein products as a novel marker of oxidative stress in uremia,” Kidney International, vol. 49, no. 5, pp. 1304–1313, 1996. View at Publisher · View at Google Scholar
  21. I. F. Benzie and J. J. Strain, “The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay,” Analytical Biochemistry, vol. 239, no. 1, pp. 70–76, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Bartosz, “Total antioxidant capacity,” Advances in Clinical Chemistry, vol. 37, pp. 219–292, 2003. View at Publisher · View at Google Scholar
  23. I. Dalle-Donne, R. Rossi, D. Giustarini, A. Milzani, and R. Colombo, “Protein carbonyl groups as biomarkers of oxidative stress,” Clinica Chimica Acta, vol. 329, no. 1-2, pp. 23–38, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. J. Suzuki, M. Carini, and D. A. Butterfield, “Protein carbonylation,” Antioxidants & Redox Signaling, vol. 12, no. 3, pp. 323–325, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Vlassopoulos, M. E. Lean, and E. Combet, “Role of oxidative stress in physiological albumin glycation: a neglected interaction,” Free Radical Biology & Medicine, vol. 60, pp. 318–324, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Wetzels, K. Wouters, C. G. Schalwijk, T. Vanmierlo, and J. Hendriks, “Methylglyoxal-derived advanced glycation endproducts in multiple sclerosis,” International Journal of Molecular Sciences, vol. 18, p. 421, 2017. View at Publisher · View at Google Scholar
  27. Z. Sternberg, C. Hennies, D. Sternberg et al., “Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosis,” Journal of Neuroinflammation, vol. 7, p. 72, 2017. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Witko-Sarsat, M. Friedlander, T. Nguyen Khoa et al., “Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure,” The Journal of Immunology, vol. 161, no. 5, pp. 2524–2532, 1998. View at Google Scholar
  29. A. Grzelak and G. Bartosz, “Melatonin does not affect total antioxidant capacity of blood plasma in vitro,” Scandinavian Journal of Clinical and Laboratory Investigations, vol. 65, no. 1, pp. 77–81, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Adamczyk-Sowa, P. Sowa, J. Adamczyk et al., “Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone,” Journal of Physiology and Pharmacology, vol. 63, no. 5, pp. 507–516, 2013. View at Google Scholar
  31. S. Emamgholipour, A. Hossein-Nezhad, M. A. Sahraian, F. Askarisadr, and M. Ansari, “Evidence for possible role of melatonin in reducing oxidative stress in multiple sclerosis through its effect on SIRT1 and antioxidant enzymes,” Life Sciences, vol. 145, pp. 34–41, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. S. A. Ganie, T. A. Dar, A. H. Bhat et al., “Melatonin: a potential anti-oxidant therapeutic agent for mitochondrial dysfunctions and related disorders,” Rejuvenation Research, vol. 19, no. 1, pp. 21–40, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. M. F. Farez, I. D. Mascanfroni, S. P. Méndez-Huergo et al., “Melatonin contributes to the seasonality of multiple sclerosis relapses,” Cell, vol. 162, no. 6, pp. 1338–1352, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Anderson and M. Rodriguez, “Multiple sclerosis: the role of melatonin and N-acetylserotonin,” Multiple Sclerosis and Related Disorders, vol. 4, no. 2, pp. 112–123, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Roostaei, M. A. Sahraian, S. Hajeaghaee et al., “Impact of melatonin on motor, cognitive and neuroimaging indices in patients with multiple sclerosis,” Iran Journal of Allergy, Asthma and Immunology, vol. 14, no. 6, pp. 589–595, 2015. View at Google Scholar